Form 4: Alnylam Executive Granted 13,026 RSUs

Bryan Supran, EVP, CLO and Secretary of Alnylam Pharmaceuticals, Inc., was granted 13,026 restricted stock units.

Summary

• Bryan Supran, Executive Vice President, Chief Legal Officer, and Secretary of Alnylam Pharmaceuticals, Inc. (ALNY), was granted 13,026 restricted stock units (RSUs).
• The RSUs were granted under the Amended and Restated 2018 Stock Incentive Plan.
• Each RSU represents a contingent right to receive one share of common stock.
• The RSUs will vest over a three-year period, with one-third vesting on each of the first, second, and third anniversaries of the grant date.
• Vesting is contingent upon Mr. Supran's continuous service with the Issuer as of each vesting date.
• The transaction date for the RSU grant was October 1, 2025.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While a routine compensation event, it signifies continued executive commitment and alignment with shareholder interests, which is generally viewed favorably. There are no negative surprises or material adverse impacts.

Positives

• The RSU grant aligns the executive's long-term interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• This grant serves as an incentive for executive retention, encouraging Mr. Supran's continued service to the company for the three-year vesting period.
• The use of RSUs is a common and accepted practice for executive compensation, reflecting standard corporate governance practices.

Negatives

• The future vesting of these RSUs will result in a minor increase in the outstanding share count, leading to slight dilution for existing shareholders, though this is typical for equity compensation plans.

Risks

• The vesting of the restricted stock units is subject to the reporting person's continuous service with the Issuer as of each vesting date, meaning the shares could be forfeited if employment ceases before vesting.

Future Outlook

The grant of restricted stock units indicates an expectation of continued service from Bryan Supran for at least the next three years, aligning his incentives with the company's long-term performance through the vesting schedule.

Industry Context

The grant of restricted stock units to key executives is a standard practice in the biotechnology and pharmaceutical industry for attracting, retaining, and incentivizing top talent. This compensation structure aligns executive interests with shareholder value creation over the long term, a common strategy in a sector characterized by long development cycles and significant R&D investment.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) as a component of executive compensation is a widely adopted practice across the biotechnology and pharmaceutical industry, comparable to compensation structures at companies like Moderna, Biogen, or Vertex Pharmaceuticals.
• The three-year vesting schedule, with annual tranches, is a common approach to ensure executive retention and incentivize sustained performance, consistent with industry benchmarks for long-term incentive plans.
• The grant price of $0.0 for RSUs is standard, as RSUs represent a right to receive shares rather than an option to purchase them at a set price.

Stakeholder Impact

• Shareholders: Experience minor potential future dilution upon vesting of the RSUs, but benefit from increased executive alignment with long-term company performance.
• Employees (specifically Bryan Supran): Receives long-term equity compensation, incentivizing continued service and performance.

Next Steps

• One-third of the granted RSUs will vest on October 1, 2026, subject to continuous service.
• An additional one-third of the granted RSUs will vest on October 1, 2027, subject to continuous service.
• The final one-third of the granted RSUs will vest on October 1, 2028, subject to continuous service.

Key Dates

Recommendation

This filing details a routine executive compensation grant of restricted stock units. Such grants are standard practice for publicly traded companies and do not typically indicate a material change in the company's fundamental outlook or valuation. Therefore, it does not warrant a change in investment recommendation based solely on this information.

Keywords

Alnylam Pharmaceuticals, ALNY, Restricted Stock Units, RSU Grant, Executive Compensation, Insider Transaction, Form 4, Equity Incentive Plan, Bryan Supran